Omnicell, Inc.

NASDAQ:OMCL

Medical - Healthcare Information Services

Healthcare
$34.66 -1.49%

-$0.58 today

Market cap
$1.59B
Beta
0.96
P/E (TTM)
84.1
EPS (TTM)
$0.45
52W Low $26.85High $55.00

Volume 0.34M

Average 0.57M

OMCL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Omnicell, Inc.NASDAQ: OMCL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $20.5M fell 6.1% year over year, in line with the -5.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Depreciation & amortization amounted to 7.3% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.1% toward the trailing-twelve-month pace of -5.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.5M+3.5% QoQ
Last fiscal yearDec 2025
$86.63M-3.5% YoY
LTMMar 2026
$83.32M-5.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.1%——
1 year-3.5%——
3-year CAGR-4.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
86.63M USD
Year-over-year change
-3.5%
4-year CAGR
+0.5%

Depreciation & Amortization vs competitors

How OMCL compares with its peers on the latest reported figures

  • OMCL's LTM Mar 2026 depreciation & amortization of $83.32M is the 2nd largest of the 11 companies compared; the peer median is $27.1M.
  • Its year-over-year change of -5.8% is the 10th highest of 11, against a peer median of +17.8%.
  • Depreciation & amortization amounts to 6.8% of revenue for OMCL, versus a peer median of 2.8%.
OMCL Competitors Peer median
Depreciation & Amortization for OMCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$370.85M -0.4%+10.7%14.7%
OMCLOmnicell, Inc.LTM Mar 2026$83.32M -5.8%-4.4%6.8%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$82.56M +10.8%+16.3%10.5%
ASTHAstrana Health, Inc.LTM Mar 2026$54.38M +83.2%+37.6%1.5%
TXG10x Genomics, Inc.LTM Jun 2026$45.93M +12.6%+9.9%7.4%
PHRPhreesia, Inc.LTM Apr 2026$34.53M +22.9%+7.5%7.0%
UFPTUFP Technologies, Inc.LTM Jun 2026$19.66M +9.0%+17.2%3.1%
PGNYProgyny, Inc.LTM Jun 2026$7.22M +79.8%+45.7%0.6%
OMDAOmada HealthLTM Mar 2026$6.61M +31.8%+8.2%2.3%
SDGRSchrödinger, Inc.LTM Sep 2026$5.86M -7.7%+11.5%2.2%
SSIISS Innovations International, Inc.LTM Mar 2026$1.19M +110.8%+123.3%2.5%
Peer median (excluding OMCL) $27.1M+17.8%+13.9%2.8%

Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income77.85M5.65M(20.37M)12.53M2.05M
Depreciation & Amortization84.93M99.17M95.56M89.76M86.63M
Deferred Income Tax(3.27M)(37.32M)(11.05M)(14.86M)(1.29M)
Stock-Based Compensation53.16M68.25M55.3M39.32M44.5M
Change in Working Capital(3.34M)(73.47M)43.67M58.33M(8.33M)
Accounts Receivables(40.97M)(60.36M)38.74M(5M)41.42M
Inventory(25.7M)(30.12M)38.02M5.39M(11.23M)
Accounts Payables29.08M(7.75M)(17.53M)7.21M(9.28M)
Other Working Capital34.24M24.76M(15.56M)50.73M(29.25M)
Other Non-Cash Items22.48M15.5M17.98M2.64M3.74M
Operating Cash Flow231.81M77.78M181.09M187.72M127.3M
Capital Expenditures(28.97M)(60.74M)(41.47M)(36.46M)(40.42M)
Acquisitions (Net)(354.16M)2.07M000
Purchases of Investments00000
Sales of Investments0(15.35M)0(10.4M)(10.17M)
Other Investing Activities(29.37M)15.35M0(5.93M)(9.78M)
Investing Cash Flow(412.5M)(58.67M)(55.02M)(52.79M)(60.36M)
Debt Repayment00(2.97M)(225.46M)(175M)
Common Stock Issued040.18M23.22M38.58M16.87M
Common Stock Repurchased(16.29M)(52.21M)00(77.6M)
Dividends Paid00000
Other Financing Activities63.65M(8.93M)3.17M(48.7M)17.42M
Financing Cash Flow47.36M(20.95M)23.42M(235.58M)(218.32M)
Effect of Forex Changes(974K)(944K)(1.35M)(1.72M)3.8M
Net Change in Cash(134.3M)(2.79M)148.14M(102.37M)(147.58M)
Free Cash Flow202.84M17.04M139.62M151.26M86.89M

Omnicell, Inc.

NASDAQ:OMCL

Intrinsic Alpha fair value

Locked

Current Price

$34.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.